The study provides mechanistic insights into how tumor cell‐intrinsic Setd2 deficiency strengthens the immune escape during pancreatic tumorigenesis, which may offer potential therapeutic implications for pancreatic cancer patients with SETD2 deficiency. Here, SETD2 is linked to neoplasm.